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Meprin β is a metalloprotease associated with neurodegeneration, inflammation,
extracellular matrix homeostasis, transendothelial cell migration, and cancer. In this
study, we investigated two melanoma-associated variants of meprin β, both exhibiting
a single amino acid exchange, namely, meprin βG45R and G89R. Based on the structural
data of meprin β and with regard to the position of the amino acid exchanges, we
hypothesized an increase in proteolytic activity in the case of the G45R variant due to the
induction of a potential new activation site and a decrease in proteolytic activity from the
G89R variant due to structural instability. Indeed, the G89R variant showed, overall, a
reduced expression level compared to wild-type meprin β, accompanied by decreased
activity and lower cell surface expression but strong accumulation in the endoplasmic
reticulum. This was further supported by the analysis of the shedding of the interleukin-6
receptor (IL-6R) by meprin β and its variants. In transfected HEK cells, the G89R variant
was found to generate less soluble IL-6R, whereas the expression of meprin β G45R
resulted in increased shedding of the IL-6R compared to wild-type meprin β and the G89R
variant. A similar tendency of the induced shedding capacity of G45R was seen for the
well-described meprin β substrate CD99. Furthermore, employing an assay for cell
migration in a collagen IV matrix, we observed that the transfection of wild-type meprin
β and the G45R variant resulted in increased migration of HeLa cells, while the G89R
variant led to diminished mobility.
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INTRODUCTION
Meprin β is a metalloprotease of the astacin family of zinc endopeptidases. As a multidomain
homodimer and a type I transmembrane protein, it is tethered to the cell surface or it can be shed
from the plasma membrane by other proteases such as ADAMs (a disintegrin and metalloproteases)
(Broder and Becker-Pauly 2013; Wichert et al., 2017; Scharfenberg et al., 2019). Expressed as a
zymogen, meprin βmust be activated by proteases with tryptic specificity due to an arginine residue
at the P1 position of the activation site. At the cell surface, the activation of meprin β can be achieved
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such as kallikrein 4/5 or pancreatic trypsin (Ohler et al., 2010). Of
note, once activated at the plasmamembrane, meprin β cannot be
shed from the cell surface anymore (Wichert et al., 2017). Hence,
meprin β occurs as a membrane-bound sheddase or soluble
protease with access to different protein substrates.
Proteolysis of extracellular matrix and adhesion molecules
is a very important factor in the context of cancer progression
and metastasis. Meprin β is capable of cleaving off the
prodomains of fibrillar collagens I and III, thereby inducing
a collagen fibril assembly and deposition (Kronenberg et al.,
2010; Broder et al., 2013). In this regard, meprin β has been
associated with fibrotic conditions of the skin and in the lungs
(Becker-Pauly et al., 2007; Biasin et al., 2014). On the other
hand, meprin β is able to degrade collagen IV, an important
component of the basal membrane, and thus may contribute to
cancer cell metastasis (Kruse et al., 2004). Furthermore,
meprin β has been shown to cleave different cell adhesion
molecules. The expression of E-cadherin, a major adhesion
molecule of the epithelium, was shown to be decreased
compared to carcinoma and adenoma (Perl et al., 1998).
Interestingly, E-cadherin is a substrate of meprin β
(Huguenin et al., 2008), which could lead, in the case of
dysregulation in the expression and functionality due to
mutations, to tumor progression from adenoma to
carcinoma. The adhesion molecule CD99 is overexpressed
in many types of cancer, particularly in Ewing sarcoma and
specific subtypes of leukemia (Manara et al., 2018; Pasello
et al., 2018). CD99 is crucial for the transendothelial migration
(TEM) of leukocytes promoting the final step of cell
extravasation. The type I transmembrane protein is
expressed on hematopoietic and endothelial cells (Jefferson
et al., 2013; Bedau et al., 2017a; Bedau et al., 2017b). Being a
substrate of meprin β, the cleavage of CD99 could influence
tumor metastasis.
Another substrate of meprin β is the interleukin-6 receptor
(IL-6R), which in its shed soluble form can induce a strong
proinflammatory stimulus via the so-called IL-6 trans-signaling
(Rose-John, 2012). Inflammatory processes and cancer
progression are highly connected, mediated by cytokines like
the IL-6R and other immunomodulatory molecules in the tumor
microenvironment (Balkwill and Mantovani 2001; Fisher et al.,
2014). It was observed that a selective blockage of IL-6 trans-
signaling with the sgp130Fc protein (Olamkicept) had a
suppressive effect on the tumorigenesis and metastasis of
colorectal cancer (Schmidt et al., 2018; Schumacher and Rose-
John 2019).
Meprin β has been associated with certain types of cancer, and its
expression was observed in pancreatic and neuroendocrine tumors
(Carr et al., 2013). Searching the BioMuta database (Dingerdissen
et al., 2018), several single nucleotide variants (SNVs) of the Mep1b
gene can be found in different cancer entities identified by multiple
genomic studies, with the largest number identified in melanoma,
uterine cancer, and lung cancer (Peters and Becker-Pauly, 2019). In
this study, we characterized the melanoma-associated meprin β
variants G45R and G89R with regard to cell surface expression,
shedding activity, cell proliferation, and tumor cell invasion.
MATERIALS AND METHODS
Chemicals
All chemicals were of analytical grade and obtained from Carl
Roth GmbH + Co. KG, Merck KGaA, and Sigma-Aldrich Inc.,
and Thermo Fisher Scientific Inc., if not stated otherwise.
Cells, Transfection, Plasmids, and
Antibodies
ADAM10−/−; 17−/− HEK293T cells (Riethmueller et al., 2016),
deficient for the metalloproteases ADAM10 and ADAM17, were
kindly provided by Björn Rabe, University of Kiel. HeLa and
COS-7 cells were obtained from DSMZ GmbH (Braunschweig,
Germany), and Ba/F3-gp130 cells (Gearing et al., 1994) were
obtained from Immunex (Seattle, WA, United States). All cells
were grown in DMEM (Dulbecco’s modified Eagle’s medium)
and high glucose culture medium (Sigma-Aldrich) supplemented
with 10% fetal calf serum (FCS), L-glutamine, and 1% penicillin
and streptomycin (Thermo Fisher Scientific) and cultured at 37°C
in 5% CO2 atmosphere and at 95% relative humidity. Ba/F3-
gp130 cells were cultured using 10 ng/ml recombinant hyper-IL-
6, which was expressed and purified as described previously
(Fischer et al., 1997). Transient transfection was performed
with polyethylenimine according to the manufacturer’s
instructions. The following plasmids were used: human
meprin β in the pcDNA4/TO-3x-Flag vector, human meprin β
G45R in the pcDNA4/TO-3x-Flag vector, humanmeprin βG89R
in the pcDNA4/TO-3x-Flag vector, human IL-6R, human CD99-
Myc in pCMV6, APP695 in pCI-neo, and pcDNA3.1 as the
empty vector control. The following antibodies were used:
polyclonal anti–meprin β (generated against the ectodomain
peptide CGMIQSSGDSADWQRVSQ, Pineda Antibody-
Service, Berlin, Germany), monoclonal anti-IL-6R (4–11,
generated against the D1 domain), monoclonal
anti–glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
(2,118, 14C10; Cell Signaling Technology, Danvers, MA,
United States), monoclonal anti-Flag (M2, F1804;
MilliporeSigma), polyclonal anti-transferrin receptor (ab84036;
Abcam, Cambridge, United Kingdom), monoclonal anti-Myc
(9B11, 2,276; Cell Signaling Technology), phosphorylated
signal transducer and activator of transcription 3 (pSTAT3)
(9,131, Y705, Cell Signaling Technology, Danvers, MA,
United States), STAT3 (9,139, 124H6, Cell Signaling
Technology, Danvers, MA, United States), monoclonal
anti–N-terminal APP (22C11; MilliporeSigma), polyclonal
C-terminal anti-APP (CT15) and monoclonal anti–soluble
APPα (6E10; Covance, Princeton, NJ, United States), and anti-
PDI6 (ab11432; Abcam, Cambridge, United Kingdom).
Generating Meprin β Variants G45R and
G89R
Using the meprin β pcDNA4/TO construct with a C-terminal
FLAG-tag as the template, the two variants G45R and G89R were
generated. For exchanging single nucleotides, we applied
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appropriate primers (meprin β G45R: 5′-CAATGAAGGTTT
GAGACTGGATCTTTTTGAGGG-3′ and 5′-CCCT CAAAAA
GATCCAGTCTCAAACCTTCATTG-3′ andmeprin βG89R: 5′-
GGAAATG AATGCTAAG CGAGTTATCCTCAATGC-3′ and
5′-GCATTGAGGATAACTCGCTTAGCATTCATTTCC-3′)
and the QuickChange II XL Site-Directed Mutagenesis Kit
(Agilent Technologies, Santa Clara, CA, United States)
following the manufacturer’s instructions. To validate the
correct single nucleotide exchanges of variants G45R and
G89R, the cDNA of the Mep1b gene was sequenced by GATC
Biotech, Konstanz, Germany.
Cell Lysis, SDS-PAGE, and Western Blot
Analysis
Transfected cells were harvested 48 h after transfection. For
C-terminal fragment analysis, cells were treated with 1 μM
γ-secretase inhibitor DAPT overnight prior to cell lysis. PBS-
washed cells were lysed in 1% Triton X-100 and the protease
inhibitor tablet with EDTA (Roche) in PBS. The protein
concentration was determined using the BCA protein assay kit
(Thermo Fisher Scientific) following the manufacturer’s
instructions. Samples were heated in sample buffer including
DTT for 10 min at 95°C. The total protein lysate (30 µg) was
separated by SDS-PAGE and transferred onto PVDF or
nitrocellulose membranes (GE Healthcare, Waukesha, WI,
United States). Membranes were blocked with 5% dry milk or
3% BSA diluted in TBS for 1 h at room temperature, incubated
overnight with the primary antibody in milk at 4°C, washed three
times with TBS, and incubated with horseradish
peroxidase–conjugated secondary antibody in TBS at room
temperature. After further washes, membranes were developed
with SuperSignal West Femto (Thermo Fisher Scientific) in a
chemiluminescence detection system (LAS-3000; Fujifilm,
Tokyo, Japan).
Protein Deglycosylation
The total protein lysate (60 µg) of transfected ADAM10−/−; 17−/−
HEK293T cells was deglycosylated using PNGase F according to
the manufacturer’s instructions (P0704; New England Biolabs,
Ipswich, MA, United States).
Cell Surface Biotinylation
ADAM10−/−; 17−/− HEK293T cells were transiently transfected
with meprin β variants or empty vectors and incubated for 24 h.
Cells were washed twice with ice-cold PBS–CaCl2 and MgCl2
(CM) (CM: 0.1 mMCaCl2 and 1 mMMgCl2 in PBS) and treated
with 1 mg/ml biotin solution (Sulfo-NHS-SS-Biotin; Thermo
Fisher Scientific) in PBS-CM for 30 min at 4°C. The biotin
solution was removed, and cells were incubated with quenching
buffer (50 mM Tris-HCl in PBS-CM, pH 8) for 10 min at 4°C,
washed three times with PBS-CM, and harvested. Subsequently,
cells were lysed and the protein concentration was determined
using the BCA assay kit following the instruction manual. For
the purification of biotin-labeled proteins, streptavidin-coated
magnetic beads (88,816, Thermo Fisher Scientific) were used
according to the manufacturer’s instructions.
Immunofluorescence Microscopy
The immunofluorescence staining of Cos-7 cells, which were
seeded on coverslips, was performed 24 h after transfection as
described previously (Peters et al., 2019). In brief, cells were
washed three times with PBS and fixed with 4% (w/v)
paraformaldehyde in PBS for 10 min. After cell
permeabilization with 0.2% (w/v) saponin, cells were incubated
with the primary antibody (anti-Flag 1:2000 and anti-PDI6 1:
1000 in 1xPBS with 10% FCS) for 1 h, washed, and then incubated
with the respective secondary antibody (Alexa Fluor 488 donkey
anti-rabbit and Alexa Fluor 594 donkey anti-mouse, 1:300;
Thermo Fisher Scientific). The excessive antibody was
removed by five washes in 0.2% (w/v) saponin and PBS and
two washes in double-distilled H2O. The coverslips were
mounted onto slides with a mixture of 17% (w/v) Mowiol,
33% (v/v) glycerol, and 50 mg/ml 1,4-diazabicyclo[2.2.2]octane
(MilliporeSigma) supplemented with 1 μg/ml DAPI for nuclear
staining. Images were acquired on an Olympus FV 1000 confocal
laser scanning microscope (Olympus, Hamburg, Germany).
Quenched Fluorogenic Peptide Cleavage
Assay
To quantify meprin β activity in cell lysates and at the cell surface,
a highly specific fluorogenic peptide substrate for meprin β [7-
methyloxycoumarin-4-yl (mca)–EDEDED–K-ε-2,4-
dinitrophenyl (dnp), Genosphere Biotechnologies, Paris,
France] was used in a final concentration of 50 µm (Jackle
et al., 2015). For meprin β cell surface activity, transfected
ADAM10−/−; 17−/− HEK293T cells were washed three times in
PBS and activity measurements were performed with 0.5 × 106
cells in 48-well plates in a total volume of 300 µl. For cell lysate
activity, cells were lysed using EDTA free lysis buffer, and a total
amount of 50 µg protein was used for the activity assays. For
trypsin activation, cells and lysates were incubated with 10 μg/ml
of recombinant trypsin (Sigma-Aldrich) for 30 min at 37°C prior
to measurement. Remaining cell suspensions were used for
Western blot analyses. All activity assays were carried out in
duplicates at 37°C. Proteolytic activity was measured as relative
fluorescence units (RFUs) every 30 s for 120 min at an excitation
of 405 nm and emission of 320 nm using the Tecan Infinite® F200
PRO plate reader (Tecan Trading AG). The activity was
determined from the slope of the linear range of the curve
normalized to the initial point of the measurement and
presented as a bar graph.
Ba/F3-gp130 STAT3 Phosphorylation Assay
The biological activity of the sIL-6R was analyzed as described
previously (Sammel et al., 2019). In brief, after washing with PBS,
Ba/F3-gp130 cells were incubated in serum-free medium for 2 h.
Cells were incubated with an ultracentrifuged (186,000 x g for 2 h
at 4°C), conditioned cell culture supernatant of ADAM10−/−;
17−/− HEK293T cells co-transfected with meprin β variants and
the IL-6R; 150 ng recombinant IL-6 was added. 150 ng hyper-IL-
6 (Fischer et al., 1997; Schroers et al., 2005) served as positive
control. Cells were incubated at 37°C and were shook for 15 min
at 500 rpm followed by centrifugation at 1000 x g for 5 min at
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room temperature. After discarding the supernatant, cells were
lysed in sample-buffer for 10 min at 95°C. Phosphorylated signal
transducer and activator of transcription 3 (p-STAT3) levels were
detected by Western blot analysis. STAT3 served as the control.
Real Time Cell Analysis Invasion Assay
A real-time cell analysis (RTCA) system was used for testing
the invasiveness of cells overexpressing meprin β and its
variants G45R and G89R. RTCA (ACEA Bio, San Diego,
CA, United States) is a method measuring the density-
dependent variation of cell population growth using a
sensitive micro-sensor system. The CIM-plate 16 used in
this experiment is a two-chamber-well within a micro-
sensor plate beneath a membrane with 8 µm pores. The top
of the membrane was coated with a layer of collagen IV
(Sigma-Aldrich C5533, 12 µg per well). The medium was
measured to detect the background impedance. HeLa cells
were transiently transfected with the meprin β variants, and
40.000 cells in a volume of 100 µl medium with 1% FCS were
transferred into the upper chamber onto the layer of collagen
IV. To prevent the cells from evaporating, the plate around
the wells was filled with sterile PBS and covered with a lid.
Pre-incubation of 1 h enabled all cells to adhere onto the layer
of collagen IV before starting the RTCA experiment. RTCA
was run for 24 h, measuring the cell index every 30 min at
37°C and 5% CO2. The cells passing through the layer of
collagen IV touching the microelectrode increased the
impedance. This was calculated automatically in the
dimensionless cell index. The equation for the cell index is
as follows: CI  (Zi–Z0)/15 Ω. Zi is the individual impedance
of each well to a certain time point and Zo is the impedance of
the time point at 15 min at the beginning. To be able to ignore
a possible variability of cell numbers between the wells, a
delta cell index was calculated and added. The formula for the
delta cell index is as follows: DCIti  CIti +
(DCIreference–CIDelta_time). Therefore, the delta cell index is
a constant number for each well representing the difference
between reference DCI and the cell index. For statistical
analysis, the area under the curve (AUC) or the end-point
number was used.
Homology Modeling
The model of the membrane-bound meprin β dimer was built
based on the crystal structure of human pro-meprin β (PDB
ID: 4GWM) and a molecular model of the membrane-bound
form, containing the EGF-like domains, the transmembrane
helix, and the C-terminal tail (Arolas et al., 2012), using the
SWISS-MODEL workspace (Waterhouse et al., 2018).
Structure visualization was carried out using PyMOL
(Schrödinger, New York, NY, United States).
Statistical Analysis
All statistical analyses were performed using Prism 8 software
(GraphPad Software, La Jolla, CA, United States) for a one-way
ANOVA followed by Tukey’s post-test. Values are expressed as
means ± sd. The null hypothesis was rejected at a value of p < 0.05.
RESULTS
Localization and Cell Surface Expression of
Meprin β Variants G45R and G89R
Based on the crystal structure of meprin β, we hypothesized a
decrease in proteolytic activity for the G89R variant, having an
additional arginine at the back of the catalytic domain at the
interface to the TRAF domain, which may disturb proper folding
(Figure 1A). The second meprin β variant G45R could insert a
potential cleavage site into the propeptide, which likely promotes
faster activation of the protease (Figure 1A). Since meprin β can
be activated at the cell surface or in its soluble shed form, it was
important to first investigate whether the cancer-associated
variants G45R and G89R are correctly transported to the cell
surface. Therefore, we performed cell surface biotinylation
experiments of transfected HEK293T cells, deficient for
ADAM10 and ADAM17, to prevent physiological ADAM-
mediated shedding of meprin β. The biotin pulldown showed
comparable cell surface levels for wild-type meprin β and the
G45R variant, whereas clearly less levels of the meprin β variant
G89R were detected at the cell surface (Figure 1B). However, it
has to be considered that, on the one hand, the overall expression
level of the meprin β variant G89R was clearly reduced in
comparison to wild-type meprin β and G45R. On the other
hand, the relative amount of the less glycosylated ER-form of
meprin β detectable at about 100 kDa (Peters et al., 2019) was
increased compared to the fully glycosylated form at about
130 kDa in the cell lysates of meprin β G89R (Supplementary
Figure S1).
Within the biotinylated fractions of the meprin β variants,
the majority of the detected meprin β corresponds to the
higher molecular mass in the case of wild-type meprin β
and its G45R variant, whereas only a similar trend was
observed for meprin β G89R (Figure 1B). This suggests that
the G89R mutation has a fold-impairing effect for meprin β
that also affects its efficient N-glycosylation and transport to
the cell surface.
The results were confirmed employing
immunofluorescence microscopy of Cos-7 cells
overexpressing the different meprin β variants (Figure 1C).
Cos-7 cells were used instead of HEK293T cells due to their
large size and better visibility of cellular compartments. While
the G45R variant showed cell surface expression comparable to
wild-type meprin β, the majority of meprin β G89R strongly
co-localized with the endoplasmic reticulum marker protein
disulfide isomerase (PDI). Overall, these results indicate that
the G89R variant is, indeed, stuck on the secretory pathway
probably due to impaired folding, causing a less efficient
glycosylation.
Activation and Proteolytic Activity of Meprin
β Variants G45R and G89R Using a Specific
Fluorogenic Peptide Substrate
In order to investigate the functional consequences on the activation
and proteolytic activity of the meprin β variants G45R and G89R, we
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initially performed activity assays in cell lysates and at the cell surface
of transiently transfected ADAM10−/−; 17−/− HEK293T cells
(Figure 2A) using a meprin β–specific fluorogenic peptide
(Figure 2B). Indeed, the meprin β G45R variant with a potential
additional activation site did show significantly increased basal activity
in cell lysates, while the cell surface activity was comparable to wild-
type meprin β (Figure 2C). However, treating cell lysates and cells
with the described pro-meprin β activator trypsin (Ohler et al., 2010;
Jackle et al., 2015) did not result in increased proteolytic activity of
meprin βG45R (Figure 2C). In the case of the G89R variant, the basal
proteolytic activity in cell lysates and at the cell surface appeared to be
very low (Figure 2C), which is likely also a result of the reduced
expression rate. Nevertheless, the addition of trypsin showed that this
meprin β variant can be activated (Figure 2C), indicating that the
amino acid exchange of G89R does not lead to a complete loss of
function mutation.
The Proteolytic Activity of Meprin β G45R
and G89R Toward IL-6R, CD99, and APP
In addition to the fluorogenic peptide-based activity assays, we, in
a next step, analyzed the proteolytic activity of the meprin β
variants G45R and G89R toward three known membrane-bound
meprin β protein substrates, namely, IL-6R, CD99, and APP.
IL-6R Shedding by Meprin β Variants
The soluble IL-6R plays an important role in cell proliferation and
inflammation through trans-signaling (Rose-John, 2012). Not
only ADAM10 and ADAM17 are capable of shedding the IL-
6R (Mullberg et al., 1992) but also several other proteases,
including meprin β (Arnold et al., 2017; Sammel et al., 2019).
Similar to the single transfection of the three meprin β variants,
the overall expression of meprin β G89R was also markedly
reduced upon co-transfection with the IL-6R compared with the
FIGURE 1 | Expression and localization of G45R, G89R, and wild-type meprin β. (A) Domain composition (left) and the dimeric structure of the metalloprotease
meprin β (right). The cartoon representation of membrane-bound meprin β based on the crystal structure of the ectodomain of human pro-meprin β (PDB: 4GWM), with
one monomer colored according to the domain composition and the other one in light gray. The close-up view on the catalytic domain (blue) in the right panel shows the
pro-peptide (orange) and the three active site histidine residues (cyan) that coordinate the zinc ion (pink). The positions of the two amino acid exchange variants
G45R and G89R are highlighted in red. Pro-peptide, CAT: catalytic domain, MAM: meprin A5 protein tyrosine phosphatase µ domain, TRAF: tumor-necrosis-factor-
receptor-associated factor domain, EGF: epidermal growth factor–like domain. The disulfide bridge between the MAM domains responsible for dimerization is indicated
as a yellow bar. (B) Transfection of ADAM10−/−; 17−/− HEK293T cells with the indicated meprin β variants. Cell surface proteins were labeled by primary amine
biotinylation, pulled down with streptavidin sepharose beads, and analyzed via immunoblotting. GAPDH and transferrin receptor (TfR) served as the loading controls. (C)
Immunofluorescence images of Cos-7 cells expressing the indicated meprin β variants (red), with the endoplasmic reticulum marker protein disulfide isomerase (PDI,
green) and DAPI-stained nuclei (blue). Scale bars, 20 µm.
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other two meprin β variants (Figure 3A, Supplementary Figures
S2A,B). In line with the observed increased activity measured in
the cell lysates (Figure 2C), co-transfection of meprin β G45R
and the IL-6R in ADAM10−/−; 17−/−HEK293T cells resulted in an
increased release of the soluble IL-6R (sIL-6R) compared to wild-
type meprin β (Figure 3A, Supplementary Figures S2A,B).
Interestingly, meprin β G89R was also able to shed the IL-6R
without further activation, albeit markedly less efficient than
wild-type meprin β (Figures 2C, 3A; Supplementary Figures
S2A,B). Normalizing the amount of generated sIL-6R to the IL-
6R/meprin β levels of the cell lysate even suggests a similar
proteolytic activity of meprin β G89R as wild-type meprin β
(Supplementary Figure S2). However, this analysis might be
rather misleading due to the obvious strongly reduced overall
expression level of meprin β G89R. Nonetheless, the results
suggest that the substrate binding to this meprin β variant has
a folding stabilizing effect that renders the protease as
proteolytically active.
In order to analyze the biological activity of the generated sIL-
6R by the different meprin β variants, Ba/F3-gp130 cells were
used. This murine pro-B-cell line (Ba/F3) is stably transfected
with the signal transducing receptor gp130 and does not express
the IL-6R endogenously (Taga and Kishimoto 1997). Therefore,
these cells require either the sIL-6R and IL-6 or hyper-IL-6 (a
chimeric fusion protein of the sIL-6R and IL-6) to induce trans-
signaling by the JAK/STAT-pathway via phosphorylation of
FIGURE 2 | Proteolytic activity of G45R, G89R, andwild-typemeprin β toward a fluorogenic peptide. ADAM10−/−; 17−/−HEK293T cells were transiently transfected
with a control plasmid (Ø) or one of the indicated meprin β variants. (A) Representative Western blot analysis of cell lysates. (B) Representation of the meprin β-specific
quenched fluorogenic peptide used for activity assays. (C) Cell lysate and cell surface meprin β activity in the absence and presence of trypsin. Data are presented as
means ± sd, and statistical analysis was assessed by the one-way ANOVA followed by Tukey’s post-test from three biological replicates. *p < 0.05, **p < 0.01,
***p < 0.001.
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FIGURE 3 |Meprin β-dependent shedding of the IL-6R and induced trans-signaling. (A) Immunoblots of ADAM10−/−; 17−/− HEK293T cells transiently transfected
with a control plasmid (Ø), IL-6R alone, and together with one of the indicated meprin β variants. Supernatants (sn) were ultracentrifuged and analyzed for sIL-6R. IL-6R
and sIL-6R were detected with an antibody directed against the D1-domain of IL-6R and meprin β with an anti-Flag antibody. GAPDH served as the loading control. Of
note, the amount of sIL-6R in the supernatant was increased upon the co-expression of G45R compared with meprin βWT. (B) Phosphorylation of STAT3 in Ba/
F3-gp130 cells stably transfected with gp130. Cells were treated with ultracentrifuged supernatants from the experiments in (A) and the phosphorylation of STAT3 was
analyzed in the presence and absence of 150 ng recombinant IL-6. The same amount of the fusion protein consisting of soluble IL-6R and IL-6 (hyper-IL-6) served as the
positive control. Phosphorylation was detected with an antibody raised against phosphorylated STAT3 (pSTAT3). Total STAT3 protein served as the loading control.
Western blot quantification of generated sIL-6R and pSTAT3 from three biologic replicates is presented in Supplementary Figure S2.
FIGURE 4 |CD99 shedding by the meprin β variants G45R and G89R. (A)CD99 construct used in this experiment, highlighting the highly conserved acidic regions
(HCRs) as blue boxes with roman numerals, the two known cleavage sites of meprin β and the C-terminal Myc-tag. (B) ADAM10−/−; 17−/−HEK293T cells were transiently
transfected with a control plasmid (Ø), CD99 alone, and together with one of the indicated meprin β variants. Cell lysates were analyzed byWestern blotting using an anti-
Flag antibody for meprin β and an anti-Myc antibody for CD99 detection (CD99 FL: CD99 full length; CD99 CTF I and CTF II: CD99 C-terminal fragments I and II).
GAPDH served as the loading control. To determine the accumulation of γ-secretase–dependent cleavage products, the specific inhibitor DAPT was applied. Western
blot quantification of generated CD99 CTFs from three biologic replicates is presented in Supplementary Figure S3.
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STAT3 (signal transducer and activator of transcription 3). In
accordance with the immunoblot analyses, Ba/F3-gp130 cells
were incubated with conditioned media from ADAM10−/−;
17−/− HEK293T cells co-transfected with the IL-6R, and each
of the three meprin β variants significantly induced STAT3
phosphorylation in dependence of the IL-6 in comparison to
the mock control (Figure 3B, Supplementary Figure S2C).
CD99 Shedding by Meprin β Variants
Meprin β was shown to shed the adhesion molecule CD99, thereby
promoting the transendothelial cell migration (TEM) of Lewis lung
carcinoma (LLC) cells (Bedau et al., 2017a). The cleavage sites were
identified in highly conserved acidic regions of CD99 (Bedau et al.,
2017a). Comparable to JAM-A, ICAM-1, and L-selectin, CD99
controls the transendothelial migration of cells from the vessel
lumen toward the interstitium for neutrophils, monocytes, and
lymphocytes (Schenkel et al., 2002; Lou et al., 2007). Here, we
investigated whether the meprin β variants G45R and G89R show
altered cleavage efficiency of CD99. Therefore, ADAM10−/−; 17−/−
HEK293T cells were transfected with a C-terminally tagged CD99
alone and together with the meprin β variants. CD99 shedding was
analyzed by the accumulation of C-terminal fragments CTF I and
CTF II in cell lysates via immunoblotting, as described previously
(Bedau et al., 2017a) (Figure 4, Supplementary Figure S3). To block
further processing of the CTF II by the γ-secretase, the γ-secretase
inhibitor N-[N-(3,5-difluorophenacetyl)-L- alanyl]-S-phenylglycine
t-butyl ester (DAPT) was added to the transfected cells. As for the
IL-6R, we observed that all variants of meprin β are capable of
shedding CD99 and generating the fragments CTF I and CTF II
(Figure 4B, Supplementary Figure S3). Similarly, the G45R variant
showed a tendency of more efficient CD99 cleavage than wild-type
meprin β, visualized by slightly increased levels of CTF I (Figure 4B,
Supplementary Figure S3). In contrast, the G89R variant showed
similar CD99 shedding capacity compared with wild-type meprin β,
even without considering the normalization of the reduced expression
of G89R relative to CD99 (Figure 4B, Supplementary Figure S3).
APP Shedding by Meprin β Variants
The altered glycosylation pattern of the meprin β variant G89R in cell
lysates and biotinylated cell surface fractions together with its
significantly reduced cell surface localization as judged by
immunofluorescence microscopy has been similarly described for
the meprin β variant D204A (Arnold et al., 2015). This mutation
likewise results in the expression of a less glycosylated meprin β ER-
form and shows only little cell surface activity compared to wild-type
meprin β. However, it has a very high β-secretase activity toward the
well-described meprin β substrate, amyloid precursor protein (APP),
demonstrated by increased Aβ peptide generation (Arnold et al.,
2015). Of note, APP processing by meprin β, either at the β-secretase
site or at the N-terminus releasing N-APP fragments, has been
observed to take place at the cell surface and even on the secretory
pathway (Figure 5A) (Schonherr et al., 2016; Scharfenberg et al.,
2019). Additionally, at leastmeprin β activity in transiently transfected
HEK293 cells correlates negatively with sAPPα levels (Armbrust et al.,
2021). The observed proteolytic activity of the meprin β G89R variant
towards CD99 and the IL-6R suggests substrate binding and
processing already on the secretory pathway. Therefore, APP
represented an ideal substrate to verify this hypothesis. In order to
do so, ADAM10−/−; 17−/− HEK293T cells were transfected with APP
alone or together with the meprin β variants. Even though these cells
are deficient for the two α-secretases ADAM10 and ADAM17, APP
processing at the α-secretase cleavage site is observed, most likely by a
FIGURE 5 | APP processing shedding by the meprin β variants G45R
and G89R. (A) APP is cleaved by meprin β in two distinct ways. On the one
hand, non-amyloidogenic N-APP fragments are produced, and on the other
hand, meprin β acts as a β-secretase, competing with α-secretase
cleavage at the cell surface. (B) ADAM10−/−; 17−/− HEK293T cells were
transiently transfected with a control plasmid (Ø), APP alone, and together
with one of the indicatedmeprin β variants. Cell lysates and supernatants were
analyzed by immunoblotting using an anti-Flag antibody for meprin β and
specific APP antibodies (N-APP: 22C11, sAPPα: 6E10, and total APP in
lysates: CT15). GAPDH served as the loading control. Western blot
quantification of generated N-APP and sAPPα from three biologic replicates is
presented in Supplementary Figure S4.
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compensatory endogenous alternative α-secretase like, e.g., ADAM9
(Asai et al., 2003). However, co-expression of wild-type meprin β and
its variants resulted in the expectedmeprin β-dependentAPP cleavage
pattern (Figure 5B), with a comparable increase of N-APP20
fragments in the supernatant and decreased sAPPα levels
(Figure 5B). Similarly, as observed for meprin β D204A, APP
processing by meprin β G89R resulted in N-APP20 cleavage.
However, in the case of meprin β G89R, sAPPα cleavage was
higher compared to meprin β wild-type and G45R (Figure 5B).
Similarly, as observed for CD99 shedding, the normalization of
meprin β G45R proteolysis to overall expression levels would
suggest that meprin β G45R is even more active than wild-type
meprin β (Supplementary Figure S4B). Taken together, these
findings suggest that meprin β G89R is, indeed, mainly
proteolytically active on the secretory pathway.
Meprin β G89R Diminishes the Invasion of
Cancer Cells Through Collagen IV
Since invasiveness is an important characteristic of cancer cells, we
investigated whether meprin β variants identified in certain tumors
have an influence on this process. Collagen IV is a major component
of the basal lamina and thus part of an important barrier separating
the epithelia fromunderlying tissues. It has been observed thatmeprin
β is capable of cleaving collagen IV, which may contribute to cancer
cell invasiveness (Kruse et al., 2004). Therefore, we analyzed the
invasivemobility of cells passing through a semipermeablemembrane
coatedwith collagen IV (Figure 6).HeLa cells transfectedwithmeprin
βWT, G45R, and G89R or mock as negative control were transferred
into wells with two chambers, divided by a layer of collagen IV
(Figure 6A). Cells passing through that layer changed the impedance
of the electrode placed on the bottom side. Therefore, the change in
impedance was equal to the number of cells, which had passed
through the layer of collagen IV. In contrast to the cell
surface–expressed meprin β WT and G45R, the expression of the
meprin β G89R variant significantly diminished the invasiveness of
HeLa cells (Figure 6B).
DISCUSSION
The dysregulation of proteolytic enzymes is often associated with
tumor progression and metastasis, for instance, by matrix
metalloproteases (MMP) degrading extracellular matrix (Winer
et al., 2018). This is often caused by an increased expression of
proteases by certain cancers, which may induce proliferation or
mobility of these cells. Latest genomic approaches revealed that
malignant hyperplasia exhibits a number of different driver or
bystander mutations and several of these were identified in
protease genes. Here, we investigated two cancer-associated
variants of the metalloprotease meprin β, namely, G45R and
G89R, both leading to an exchange of the amino acid glycine to
arginine. We functionally characterized these variants in biochemical
and cell biological approaches to determine possible consequences for
cancer cell invasiveness.
Based on the crystal structure of meprin β (Arolas et al., 2012), we
decided to investigate the biochemical properties and enzymatic
functions of the meprin β variants G45R and G89R. The G45R
mutation is located within the propeptide of meprin β. Knowing that
the cleavage of the propeptide occurs C-terminal of the arginine at
position 61 (Jackle et al., 2015), the insertion of another arginine in
close proximity could lead to an enhanced activation of meprin β. For
the G89R variant, we presumed that the insertion of arginine with a
big positively charged sidechain into the very tight area between the
catalytic domain and the TRAF domain would have a negative effect
on the proteolytic activity due to impaired folding of the protein.
Indeed, we observed decreased levels of fully glycosylated G89R in
cell lysates and at the plasma membrane compared to wild-type
meprin β. Along the same lines, we detected higher amounts of the
less glycosylated ER-form ofmeprin β in the case of the G89R variant.
This indicates that the G89R variant was partially stuck on the
FIGURE 6 | Cancer cell invasion assay through collagen IV matrix. (A) HeLa cells were transfected and seeded into the upper chamber of the well, and the
impedance of the electrode located at the bottom of the well was measured for 24 h. An increase in impedance was equal to cell invasion through the layer of collagen IV.
(B) Quantification of the results demonstrates that the expression of G89R reduced the invasiveness significantly. Values of the different meprin β variants were
normalized to values of mock-transfected cells, which were set as 1. Data are presented as means ± sd, and statistical analysis was assessed by the one-way
ANOVA followed by Tukey’s post-test from three biologic replicates. *p < 0.05, **p < 0.01, ***p < 0.001.
Frontiers in Molecular Biosciences | www.frontiersin.org October 2021 | Volume 8 | Article 7023419
Gellrich et al. Meprin Beta Cancer-Associated Variants
secretory pathway, which could be confirmed by the
immunofluorescence analysis where an ER-marker (PDI) showed
strong co-localization with G89R. This observation was further
supported by a markedly reduced proteolytic activity of this
meprin β variant on the plasma membrane of living cells.
Nonetheless, considering the protein substrate analyses including
APP processing, it turned out that substrate binding on the
secretory pathway seems to have a folding stabilizing effect, which
enables G89R activation and, therefore, proteolytic activity toward
substrates before reaching the cell surface.
Analyzing the meprin β G45R variant, we expected the protease to
be faster activated due to the inserted arginine in position 45,
representing a potential additional activation site, besides the
arginine in position 61 that is cleaved by pancreatic trypsin and
matriptase 2 (Ohler et al., 2010; Jackle et al., 2015). This was, indeed,
true for the basal activity; however, we did not observe increased
proteolytic activity on cells expressing the G45R variant when
incubated with trypsin. In studies investigating a meprin β G32R
variant, the additional arginine, indeed, resulted in increased cell
surface activity of meprin β (Schäffler et al., 2019). Analyzing the
proteolytic processing of protein substrates, G45R showed a tendency
of increased activity compared to wild-type meprin β. One
explanation why G45R is less prone to an increased activation
than G32R could be the position of the mutation within the
propeptide. In pro-meprin β, the propeptide interacts via two salt
bridges on the prime site (D30-R146 and D34-R146) and two on the
non-prime site (R54-E137 and D56-R131) with the catalytic domain
(Arolas et al., 2012). Therefore, it is possible that G32R has a more
destabilizing impact by disrupting the prime site interaction than
G45R, which is located in themiddle of the two important interaction
sites. Consequently, G32R leads to more pronounced meprin β
activity at the cell surface, while the effect of G45R is rather moderate.
IL-6 classic- and trans-signaling are important mechanisms in
immunomodulation, promoting immune cell differentiation and
proliferation (Rose-John, 2012). For trans-signaling cleavage of the
IL-6 receptor by ectodomain sheddases, such as ADAM17 or meprin
β, it is mandatory to act on cells that do not express the receptor
endogenously (Arnold et al., 2017; Sammel et al., 2019). The pro-B-
cell line Ba/F3-gp130 is dependent on IL-6 trans-signaling as an
inducer of proliferation (Sammel et al., 2019). In this study, we could
show that the IL-6R cleavage was increased by the meprin β variant
G45R in comparison to the wild-type enzyme, which could influence
cancer and immune cell proliferation.
Themeprin β substrate CD99was observed to promote cancer cell
extravasation (Bedau et al., 2017a; Bedau et al., 2017b). However,
whether the persistent cleavage by the G45R and G89R variants as
shown in this study has influence on cell migration in melanoma has
to be further demonstrated (Wilkerson et al., 2006).
Natural tissue barriers such as the basal membrane are important
factors for tumor progression and tumor metastasis (Tanjore and
Kalluri 2006). Meprin β has been shown to hydrolyze collagen IV
(Kruse et al., 2004), a major component of the basement membrane.
Therefore, we investigated whether one of the protease variants would
have an impact on the invasiveness of tumor cells in vitro. Testing the
invasiveness of Hela cells expressing the different variants of meprin β
revealed that meprin β in its active form on the cell surface (variant
G45R undWT) is more capable of passing through a layer of collagen
IV. Although the difference was not huge, an alternation of the
proteolytic activity of meprin β likely affects the invasiveness of tumor
cells. This result was in line with the results of the G32R variant
(Schäffler et al., 2019), thus indicating a possible pro-metastatic
function of meprin β.
Taken together, here we characterized biochemically and in
cell-based assays the two annotated cancer-associated meprin β
amino exchange variants G45R and G89R, indicating
controversial functions on cancer progression. On the one
hand, we identified potentially cancer-promoting functions of
G45R, such as increased proteolytic activity at the cell surface. On
the other hand, G89R showed overall reduced expression levels
and was mainly active on the secretory pathway and only partially
reached the plasma membrane. This rather indicates
antitumorogenic properties particularly for meprin β
substrates, which can be processed solely at the plasma
membrane or substrates of the extracellular matrix, as shown
by the cell invasion assay. Hence, future studies will show if the
characterized meprin β variants are bystanders or driver
mutations in melanoma.
DATA AVAILABILITY STATEMENT
The original contributions presented in the study are included in
the article/Supplementary Material; further inquiries can be
directed to the corresponding author.
AUTHOR CONTRIBUTIONS
AG, FS, MS, FreS, PA, and FP designed and performed
experiments. AG, FS, and CB-P analyzed the data and wrote
the manuscript. OH, SS, FA, JL, and CG provided material and
technical support.
FUNDING
This work was supported by the Deutsche
Forschungsgemeinschaft (DFG, German Research Foundation)
SFB877 (Proteolysis as a Regulatory Event in Pathophysiology,
Projects A9, A13, A14, and A15). The authors declare no conflict
of interest.
ACKNOWLEDGMENTS
The authors thank Jessica Falkowski und Melanie Boß for
excellent technical assistance.
SUPPLEMENTARY MATERIAL
The SupplementaryMaterial for this article can be found online at:
https://www.frontiersin.org/articles/10.3389/fmolb.2021.702341/
full#supplementary-material
Frontiers in Molecular Biosciences | www.frontiersin.org October 2021 | Volume 8 | Article 70234110
Gellrich et al. Meprin Beta Cancer-Associated Variants
REFERENCES
Armbrust, F., Bickenbach, K., Koudelka, T., Tholey, A., Pietrzik, C., and Becker-
Pauly, C. (2021). Phosphorylation of Meprin β Controls its Cell Surface
Abundance and Subsequently Diminishes Ectodomain Shedding. FASEB j.
35 (7), e21677. doi:10.1096/fj.202100271R
Arnold, P., Boll, I., Rothaug, M., Schumacher, N., Schmidt, F., Wichert, R., et al.
(2017). Meprin Metalloproteases Generate Biologically Active Soluble
Interleukin-6 Receptor to Induce Trans-signaling. Sci. Rep. 7, 44053.
doi:10.1038/srep44053
Arnold, P., Schmidt, F., Prox, J., Zunke, F., Pietrzik, C., Lucius, R., et al. (2015).
Calcium Negatively Regulates Meprin β Activity and Attenuates Substrate
Cleavage. FASEB J. 29 (8), 3549–3557. doi:10.1096/fj.15-272310
Arolas, J. L., Broder, C., Jefferson, T., Guevara, T., Sterchi, E. E., Bode, W., et al.
(2012). Structural Basis for the Sheddase Function of Human Meprin
Metalloproteinase at the Plasma Membrane. Proc. Natl. Acad. Sci. 109 (40),
16131–16136. doi:10.1073/pnas.1211076109
Asai, M., Hattori, C., Szabó, B., Sasagawa, N., Maruyama, K., Tanuma, S.-i., et al.
(2003). Putative Function of ADAM9, ADAM10, and ADAM17 as APP
-secretase. Biochem. Biophysical Res. Commun. 301 (1), 231–235.
doi:10.1016/s0006-291x(02)02999-6
Balkwill, F., and Mantovani, A. (2001). Inflammation and Cancer: Back to
Virchow? The Lancet 357 (9255), 539–545. doi:10.1016/S0140-6736(00)
04046-0
Becker-Pauly, C., Höwel, M., Walker, T., Vlad, A., Aufenvenne, K., Oji, V., et al.
(2007). The α and β Subunits of the Metalloprotease Meprin Are Expressed in
Separate Layers of Human Epidermis, Revealing Different Functions in
Keratinocyte Proliferation and Differentiation. J. Invest. Dermatol. 127 (5),
1115–1125. doi:10.1038/sj.jid.5700675
Bedau, T., Peters, F., Prox, J., Arnold, P., Schmidt, F., Finkernagel, M., et al. (2017a).
Ectodomain Shedding of CD99 within Highly Conserved Regions Is Mediated
by the Metalloprotease Meprin β and Promotes Transendothelial Cell
Migration. FASEB j. 31 (3), 1226–1237. doi:10.1096/fj.201601113R
Bedau, T., Schumacher, N., Peters, F., Prox, J., Arnold, P., Koudelka, T., et al.
(2017b). Cancer-associated Mutations in the Canonical Cleavage Site Do Not
Influence CD99 Shedding by the Metalloprotease Meprin β but Alter Cell
Migration In Vitro. Oncotarget 8 (33), 54873–54888. doi:10.18632/
oncotarget.18966
Biasin, V., Marsh, L. M., Egemnazarov, B., Wilhelm, J., Ghanim, B., Klepetko, W.,
et al. (2014). Meprinβ, a Novel Mediator of Vascular Remodelling Underlying
Pulmonary Hypertension. J. Pathol. 233 (1), 7–17. doi:10.1002/path.4303
Broder, C., Arnold, P., Vadon-Le Goff, S., Konerding, M. A., Bahr, K., Muller, S.,
et al. (2013). Metalloproteases Meprin and Meprin Are C- and N-Procollagen
Proteinases Important for Collagen Assembly and Tensile Strength. Proc. Natl.
Acad. Sci. 110 (35), 14219–14224. doi:10.1073/pnas.1305464110
Broder, C., and Becker-Pauly, C. (2013). The Metalloproteases Meprin α and
Meprin β: Unique Enzymes in Inflammation, Neurodegeneration, Cancer and
Fibrosis. Biochem. J. 450 (2), 253–264. doi:10.1042/BJ20121751
Carr, J. C., Sherman, S. K., Wang, D., Dahdaleh, F. S., Bellizzi, A. M., O’Dorisio, M.
S., et al. (2013). Overexpression of Membrane Proteins in Primary and
Metastatic Gastrointestinal Neuroendocrine Tumors. Ann. Surg. Oncol. 20
(Suppl. 3), 739–746. doi:10.1245/s10434-013-3318-6
Dingerdissen, H. M., Torcivia-Rodriguez, J., Hu, Y., Chang, T.-C., Mazumder, R.,
and Kahsay, R. (2018). BioMuta and BioXpress: Mutation and Expression
Knowledgebases for Cancer Biomarker Discovery. Nucleic Acids Res. 46 (D1),
D1128–D1136. doi:10.1093/nar/gkx907
Fischer, M., Goldschmitt, J., Peschel, C., Brakenhoff, J. P. G., Kallen, K.-J., Wollmer,
A., et al. (1997). A Bioactive Designer Cytokine for Human Hematopoietic
Progenitor Cell Expansion. Nat. Biotechnol. 15 (2), 142–145. doi:10.1038/
nbt0297-142
Fisher, D. T., Appenheimer, M. M., and Evans, S. S. (2014). The Two Faces of IL-6
in the Tumor Microenvironment. Semin. Immunol. 26 (1), 38–47. doi:10.1016/
j.smim.2014.01.008
Gearing, D. P., Ziegler, S. F., Comeau, M. R., Friend, D., Thoma, B., Cosman, D.,
et al. (1994). Proliferative Responses and Binding Properties of Hematopoietic
Cells Transfected with Low-Affinity Receptors for Leukemia Inhibitory Factor,
Oncostatin M, and Ciliary Neurotrophic Factor. Proc. Natl. Acad. Sci. 91 (3),
1119–1123. doi:10.1073/pnas.91.3.1119
Huguenin, M., Müller, E. J., Trachsel-Rösmann, S., Oneda, B., Ambort, D., Sterchi,
E. E., et al. (2008). The Metalloprotease Meprinβ Processes E-Cadherin and
Weakens Intercellular Adhesion. PLoS One 3 (5), e2153. doi:10.1371/
journal.pone.0002153
Jäckle, F., Schmidt, F., Wichert, R., Arnold, P., Prox, J., Mangold, M., et al. (2015).
Metalloprotease Meprin β Is Activated by Transmembrane Serine Protease
Matriptase-2 at the Cell Surface Thereby Enhancing APP Shedding. Biochem. J.
470 (1), 91–103. doi:10.1042/BJ20141417
Jefferson, T., auf dem Keller, U., Bellac, C., Metz, V. V., Broder, C., Hedrich, J., et al.
(2013). U. Auf Dem KellerThe Substrate Degradome of Meprin
Metalloproteases Reveals an Unexpected Proteolytic Link between Meprin β
and ADAM10. Cell. Mol. Life Sci. 70 (2), 309–333. doi:10.1007/s00018-012-
1106-2
Kronenberg, D., Bruns, B. C., Moali, C., Vadon-Le Goff, S., Sterchi, E. E., Traupe,
H., et al. (2010). Processing of Procollagen III by Meprins: New Players in
Extracellular Matrix Assembly? J. Invest. Dermatol. 130 (12), 2727–2735.
doi:10.1038/jid.2010.202
Kruse, M.-N., Becker, C., Lottaz, D., Köhler, D., Yiallouros, I., Krell, H.-W., et al.
(2004). Human Meprin Alpha and Beta Homo-Oligomers: Cleavage of
Basement Membrane Proteins and Sensitivity to Metalloprotease Inhibitors.
Biochem. J. 378 (Pt 2), 383–389. doi:10.1042/BJ20031163
Lou, O., Alcaide, P., Luscinskas, F. W., and Muller, W. A. (2007). CD99 Is a Key
Mediator of the Transendothelial Migration of Neutrophils. J. Immunol. 178
(2), 1136–1143. doi:10.4049/jimmunol.178.2.1136
Manara, M., Pasello, M., and Scotlandi, K. (2018). CD99: A Cell Surface Protein
with an Oncojanus Role in Tumors.Genes 9 (3), 159. doi:10.3390/genes9030159
Müllberg, J., Schooltink, H., Stoyan, T., Heinrich, P. C., and Rose-John, S. (1992).
Protein Kinase C Activity Is Rate Limiting for Shedding of the Interleukin-6
Receptor. Biochem. Biophysical Res. Commun. 189 (2), 794–800. doi:10.1016/
0006-291x(92)92272-y
Ohler, A., Debela, M., Wagner, S., Magdolen, V., and Becker-Pauly, C. (2010).
Analyzing the Protease Web in Skin: Meprin Metalloproteases Are Activated
Specifically by KLK4, 5 and 8 Vice Versa Leading to Processing of proKLK7
Thereby Triggering its Activation. Biol. Chem. 391 (4), 455–460. doi:10.1515/
BC.2010.023
Pasello, M., Manara, M. C., and Scotlandi, K. (2018). CD99 at the Crossroads of
Physiology and Pathology. J. Cel Commun. Signal. 12 (1), 55–68. doi:10.1007/
s12079-017-0445-z
Perl, A.-K., Wilgenbus, P., Dahl, U., Semb, H., and Christofori, G. (1998). A Causal
Role for E-Cadherin in the Transition from Adenoma to Carcinoma. Nature
392 (6672), 190–193. doi:10.1038/32433
Peters, F., and Becker-Pauly, C. (2019). Role of Meprin Metalloproteases in
Metastasis and Tumor Microenvironment. Cancer Metastasis Rev. 38 (3),
347–356. doi:10.1007/s10555-019-09805-5
Peters, F., Scharfenberg, F., Colmorgen, C., Armbrust, F., Wichert, R., Arnold, P.,
et al. (2019). Tethering Soluble Meprin α in an Enzyme Complex to the Cell
Surface Affects IBD-associated Genes. FASEB j. 33 (6), 7490–7504. doi:10.1096/
fj.201802391R
Riethmueller, S., Ehlers, J. C., Lokau, J., Düsterhöft, S., Knittler, K., Dombrowsky,
G., et al. (2016). Cleavage Site Localization Differentially Controls Interleukin-6
Receptor Proteolysis by ADAM10 and ADAM17. Sci. Rep. 6, 25550.
doi:10.1038/srep25550
Rose-John, S. (2012). IL-6 Trans-signaling via the Soluble IL-6 Receptor:
Importance for the Pro-inflammatory Activities of IL-6. Int. J. Biol. Sci. 8
(9), 1237–1247. doi:10.7150/ijbs.4989
Sammel, M., Peters, F., Lokau, J., Scharfenberg, F., Werny, L., Linder, S., et al.
(2019). Differences in Shedding of the Interleukin-11 Receptor by the Proteases
ADAM9, ADAM10, ADAM17, Meprin α, Meprin β and MT1-MMP. Ijms 20
(15), 3677. doi:10.3390/ijms20153677
Schäffler, H., Li, W., Helm, O., Krüger, S., Böger, C., Peters, F., et al. (2019). The
Cancer Associated Meprin βVariant p.G32R Provides an Additional Activation
Site and Promotes Cancer Cell Invasion. J. Cel Sci 132 (11), jcs220665.
doi:10.1242/jcs.220665
Scharfenberg, F., Armbrust, F., Marengo, L., Pietrzik, C., and Becker-Pauly, C.
(2019). Regulation of the Alternative β-secretase Meprin β by ADAM-Mediated
Frontiers in Molecular Biosciences | www.frontiersin.org October 2021 | Volume 8 | Article 70234111
Gellrich et al. Meprin Beta Cancer-Associated Variants
Shedding. Cel. Mol. Life Sci. 76 (16), 3193–3206. doi:10.1007/s00018-019-
03179-1
Schenkel, A. R., Mamdouh, Z., Chen, X., Liebman, R. M., andMuller, W. A. (2002).
CD99 Plays a Major Role in the Migration of Monocytes through Endothelial
Junctions. Nat. Immunol. 3 (2), 143–150. doi:10.1038/ni749
Schmidt, S., Schumacher, N., Schwarz, J., Tangermann, S., Kenner, L., Schlederer,
M., et al. (2018). ADAM17 Is Required for EGF-R-Induced Intestinal Tumors
via IL-6 Trans-signaling. J. Exp. Med. 215 (4), 1205–1225. doi:10.1084/
jem.20171696
Schönherr, C., Bien, J., Isbert, S., Wichert, R., Prox, J., Altmeppen, H., et al. (2016).
Generation of Aggregation Prone N-Terminally Truncated Amyloid β Peptides
by Meprin β Depends on the Sequence Specificity at the Cleavage Site. Mol.
Neurodegeneration 11, 19. doi:10.1186/s13024-016-0084-5
Schroers, A., Hecht, O., Kallen, K. J., Pachta, M., Rose-John, S., and
Grotzinger, J. (2005). Dynamics of the Gp130 Cytokine Complex: a
Model for Assembly on the Cellular Membrane. Protein Sci. 14 (3),
783–790. doi:10.1110/ps.041117105
Schumacher, N., and Rose-John, S. (2019). ADAM17 Activity and IL-6 Trans-
signaling in Inflammation and Cancer. Cancers 11 (11), 1736. doi:10.3390/
cancers11111736
Taga, T., and Kishimoto, T. (1997). Gp130 and the Interleukin-6 Family of
Cytokines. Annu. Rev. Immunol. 15, 797–819. doi:10.1146/
annurev.immunol.15.1.797
Tanjore, H., and Kalluri, R. (2006). The Role of Type IV Collagen and Basement
Membranes in Cancer Progression and Metastasis. Am. J. Pathol. 168 (3),
715–717. doi:10.2353/ajpath.2006.051321
Waterhouse, A., Bertoni, M., Bienert, S., Studer, G., Tauriello, G., Gumienny, R.,
et al. (2018). SWISS-MODEL: Homology Modelling of Protein Structures and
Complexes. Nucleic Acids Res. 46 (W1), W296–W303. doi:10.1093/nar/gky427
Wichert, R., Ermund, A., Schmidt, S., Schweinlin, M., Ksiazek, M., Arnold, P., et al.
(2017). Mucus Detachment by Host Metalloprotease Meprin β Requires
Shedding of its Inactive Pro-form, Which Is Abrogated by the Pathogenic
Protease RgpB. Cel Rep. 21 (8), 2090–2103. doi:10.1016/j.celrep.2017.10.087
Wilkerson, A. E., Glasgow, M. A., and Hiatt, K. M. (2006). Immunoreactivity of
CD99 in Invasive Malignant Melanoma. J. Cutan. Pathol. 33 (10), 663–666.
doi:10.1111/j.1600-0560.2006.00524.x
Winer, A., Adams, S., and Mignatti, P. (2018). Matrix Metalloproteinase Inhibitors
in Cancer Therapy: Turning Past Failures into Future Successes. Mol. Cancer
Ther. 17 (6), 1147–1155. doi:10.1158/1535-7163.MCT-17-0646
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Publisher’s Note: All claims expressed in this article are solely those of the authors
and do not necessarily represent those of their affiliated organizations, or those of
the publisher, the editors and the reviewers. Any product that may be evaluated in
this article, or claim that may be made by its manufacturer, is not guaranteed or
endorsed by the publisher.
Copyright © 2021 Gellrich, Scharfenberg, Peters, Sammel, Helm, Armbrust, Schmidt,
Lokau, Garbers, Sebens, Arnold and Becker-Pauly. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) and the copyright owner(s) are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with
these terms.
Frontiers in Molecular Biosciences | www.frontiersin.org October 2021 | Volume 8 | Article 70234112
Gellrich et al. Meprin Beta Cancer-Associated Variants
